As the CD22 receptor is a prevalent therapeutic target in ALL treatment (CD22 is present in >90% malignant B-lineage cells), the monoclonal antibody against CD22 antigen can specifically target leukemic B-cells. Here, CD22 is linked to acute lymphoblastic leukemia.